Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation at two conferences in May.
|Deutsche Bank 40th Annual Health Care Conference|
|Date:||Wednesday May 6|
|Location:||Intercontinental Hotel, Boston|
|Company Representative:||Dr. Yaron Daniely, President & CEO|
|IATI Biomed 2015|
|Date:||Wednesday May 13|
|Location:||Tel Aviv Convention Center|
|Company Representative:||Dr. Tomer Berkovitz, CFO|
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults and adolescents with ADHD and has completed a Phase III study in adults with ADHD. The company is conducting a Phase II trial in adolescents and adults with Fragile X Syndrome. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.